Sprint: Pharma Sales Model for DTx-Drug Combination (Part 1)

While the combination of a drug with a DTx can increase the treatment value, there are many challenges when trying to fit these combinations into the pharma traditional sales model. What are the main obstacles and what would a good sales model look like for DTx+drug combinations? In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. At the end of the session, HealthXL will put together an output with the learnings from the group.